AR034985A1 - Compuesto biciclico; produccion y uso del mismo - Google Patents

Compuesto biciclico; produccion y uso del mismo

Info

Publication number
AR034985A1
AR034985A1 ARP020102986A ARP020102986A AR034985A1 AR 034985 A1 AR034985 A1 AR 034985A1 AR P020102986 A ARP020102986 A AR P020102986A AR P020102986 A ARP020102986 A AR P020102986A AR 034985 A1 AR034985 A1 AR 034985A1
Authority
AR
Argentina
Prior art keywords
ring
substituted
compound
group
production
Prior art date
Application number
ARP020102986A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR034985A1 publication Critical patent/AR034985A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)

Abstract

La presente provee un nuevo compuesto cíclico que tiene una actividad antagonista del CCR, especialmente una actividad antagonista del CCR5, y el uso del mismo. El compuesto de la presente está representado por la fórmula (1) en donde: R1 es un anillo de 5 a 6 miembros que puede estar sustituido; X1 es un enlace o similares; el anillo A es un anillo de 5 a 6 miembros que puede estar sustituido; el anillo B es un anillo de 8 a 10 miembros que puede estar sustituido; X2 es un grupo bivalente de 1 a 4 átomos; Z1 es un grupo de anillo cíclico bivalente o similares; Z2 es un enlace o similares; y R2 es un grupo amino, un grupo heterocíclico con contenido de nitrógeno que puede estar sustituido, o una sal del mismo.
ARP020102986A 2001-08-08 2002-08-07 Compuesto biciclico; produccion y uso del mismo AR034985A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12

Publications (1)

Publication Number Publication Date
AR034985A1 true AR034985A1 (es) 2004-03-24

Family

ID=26620186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102986A AR034985A1 (es) 2001-08-08 2002-08-07 Compuesto biciclico; produccion y uso del mismo

Country Status (14)

Country Link
US (7) US7371772B2 (es)
EP (3) EP1889839B1 (es)
JP (4) JP4316203B2 (es)
AR (1) AR034985A1 (es)
AT (2) ATE539062T1 (es)
AU (1) AU2002328092A1 (es)
CA (2) CA2607992A1 (es)
DE (1) DE60235632D1 (es)
DK (2) DK2206702T3 (es)
ES (2) ES2376855T3 (es)
HK (1) HK1142886A1 (es)
PE (1) PE20030329A1 (es)
PT (2) PT2206702E (es)
WO (1) WO2003014105A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1889839B1 (en) * 2001-08-08 2013-11-06 Tobira Therapeutics, Inc. Bicyclic compound, production and use as HIV inhibitors
WO2003076411A1 (fr) * 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
WO2004069833A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 縮環ピリジン誘導体、その製造法および用途
EP1593681A4 (en) * 2003-02-07 2007-09-05 Takeda Pharmaceutical TRICYCLIC COMPOUND, PROCESS FOR PRODUCTION AND USE THEREOF
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
CA2562388A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CN102256970A (zh) * 2008-10-17 2011-11-23 因瓦斯科医疗有限公司 用于治疗肾活素-血管紧张素醛固酮系统(raas)相关性障碍的组合物以及方法
SI3133070T1 (sl) 2009-11-27 2019-11-29 Genzyme Corp Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta
WO2011121558A1 (en) 2010-04-02 2011-10-06 Phivco-1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
MA39748A (fr) 2014-03-21 2021-04-21 Tobira Therapeutics Inc Cenicriviroc pour le traitement de la fibrose
MA39991A (fr) * 2014-06-02 2015-12-10 Tobira Therapeutics Inc Cénicriviroc pour le traitement de l'infection à vih-2
MX2017003215A (es) 2014-09-12 2018-01-24 Tobira Therapeutics Inc Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
KR20170097735A (ko) 2014-12-23 2017-08-28 토비라 쎄라퓨틱스, 인크. 세니크리비록 및 관련된 유사체들을 만드는 공정
KR20170113596A (ko) 2015-02-10 2017-10-12 토비라 쎄라퓨틱스, 인크. 섬유증의 치료를 위한 세니크리비록
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
CA3028151A1 (en) * 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
US10301287B2 (en) * 2016-08-31 2019-05-28 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US11155523B2 (en) 2016-12-09 2021-10-26 Medshine Discovery, Inc. Biphenyl compound as CCR2/CCR5 receptor antagonist
MX2019009909A (es) 2017-02-24 2019-10-14 Genfit Composiciones farmaceuticas para terapia de combinacion.
WO2019149089A1 (zh) 2018-02-02 2019-08-08 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
US20230002360A1 (en) * 2019-06-24 2023-01-05 Shenzhen Lingfang Biotech Co.,Ltd Heterocycloalkyl compounds as CCR2 / CCR5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2021233349A1 (zh) 2020-05-22 2021-11-25 南京明德新药研发有限公司 吡啶类衍生物及其应用
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
ATE199721T1 (de) 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd Phosphonsäure verbindungen imre herstellung und verwendung
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
DK1038525T3 (da) 1997-10-20 2004-08-02 Dainippon Pharmaceutical Co Stabiliseret farmaceutisk præparat af tetrahydropyrrolo[1,2-a]pyrazin-4-spiro-3'-pyrrolidin
CA2304959A1 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
WO2000010965A2 (en) * 1998-08-20 2000-03-02 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
WO2000037455A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
US6858230B1 (en) 1999-04-12 2005-02-22 Shionogi & Co., Ltd. Process for producing medicinal composition of basic hydrophobic medicinal compound
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
EP1889839B1 (en) * 2001-08-08 2013-11-06 Tobira Therapeutics, Inc. Bicyclic compound, production and use as HIV inhibitors
WO2003076411A1 (fr) 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
CA2562388A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2011121558A1 (en) 2010-04-02 2011-10-06 Phivco-1 Llc Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
WO2012068366A2 (en) 2010-11-18 2012-05-24 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
JP6178788B2 (ja) 2011-06-27 2017-08-09 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド
JP6391674B2 (ja) 2013-05-15 2018-09-19 トビラ セラピューティクス， インコーポレイテッド セニクリビロック組成物並びにその製造及び使用方法
MA39748A (fr) 2014-03-21 2021-04-21 Tobira Therapeutics Inc Cenicriviroc pour le traitement de la fibrose
KR20170097735A (ko) 2014-12-23 2017-08-28 토비라 쎄라퓨틱스, 인크. 세니크리비록 및 관련된 유사체들을 만드는 공정
KR20170113596A (ko) 2015-02-10 2017-10-12 토비라 쎄라퓨틱스, 인크. 섬유증의 치료를 위한 세니크리비록

Also Published As

Publication number Publication date
DK1423376T3 (da) 2010-06-28
PT1423376E (pt) 2010-04-12
US20200297700A1 (en) 2020-09-24
ES2339340T3 (es) 2010-05-19
JP2007084578A (ja) 2007-04-05
EP1423376B1 (en) 2010-03-10
WO2003014105A9 (en) 2003-11-20
HK1142886A1 (en) 2010-12-17
EP2206702A1 (en) 2010-07-14
US20120232028A1 (en) 2012-09-13
US20090030032A1 (en) 2009-01-29
CA2459172C (en) 2011-07-05
US7371772B2 (en) 2008-05-13
AU2002328092A1 (en) 2003-02-24
ES2376855T3 (es) 2012-03-20
EP1889839A1 (en) 2008-02-20
ATE460406T1 (de) 2010-03-15
US20080161287A1 (en) 2008-07-03
EP1889839B1 (en) 2013-11-06
DK2206702T3 (da) 2012-02-13
CA2607992A1 (en) 2003-02-20
EP1423376A1 (en) 2004-06-02
US20190038604A1 (en) 2019-02-07
PT2206702E (pt) 2012-02-03
US8183273B2 (en) 2012-05-22
US8741943B2 (en) 2014-06-03
JP4316203B2 (ja) 2009-08-19
US8362058B2 (en) 2013-01-29
JP2003335776A (ja) 2003-11-28
JP2013136629A (ja) 2013-07-11
JP4358851B2 (ja) 2009-11-04
JP5275148B2 (ja) 2013-08-28
WO2003014105A1 (en) 2003-02-20
US10045968B2 (en) 2018-08-14
JP2009209154A (ja) 2009-09-17
US20160008326A1 (en) 2016-01-14
DE60235632D1 (de) 2010-04-22
US20040259876A1 (en) 2004-12-23
ATE539062T1 (de) 2012-01-15
CA2459172A1 (en) 2003-02-20
EP2206702B1 (en) 2011-12-28
PE20030329A1 (es) 2003-05-12

Similar Documents

Publication Publication Date Title
AR034985A1 (es) Compuesto biciclico; produccion y uso del mismo
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
TW201129553A (en) Dipeptidyl peptidase inhibitors
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
EA200702080A1 (ru) Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
ECSP045221A (es) Sales de valsartan
RS51943B (en) PIPERIDINSKI GPCR AGONIST
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
BR0311771A (pt) Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
AR011913A1 (es) Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
BR0108303A (pt) Derivados do 1h-imidazopiridina
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
DE60322877D1 (de) Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
GEP20084361B (en) Piperidinylcarbonyl-pyrro-lidines and their use as melanocortin agonists
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
DE60318826D1 (de) Alkoxypyridinderivate
AR055420A1 (es) Derivados de pirimidina sustituidos
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal